BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 26314797)

  • 1. Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Permuth-Wey J; Chen DT; Fulp WJ; Yoder SJ; Zhang Y; Georgeades C; Husain K; Centeno BA; Magliocco AM; Coppola D; Malafa M
    Cancer Prev Res (Phila); 2015 Sep; 8(9):826-34. PubMed ID: 26314797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A genome-wide investigation of microRNA expression identifies biologically-meaningful microRNAs that distinguish between high-risk and low-risk intraductal papillary mucinous neoplasms of the pancreas.
    Permuth-Wey J; Chen YA; Fisher K; McCarthy S; Qu X; Lloyd MC; Kasprzak A; Fournier M; Williams VL; Ghia KM; Yoder SJ; Hall L; Georgeades C; Olaoye F; Husain K; Springett GM; Chen DT; Yeatman T; Centeno BA; Klapman J; Coppola D; Malafa M
    PLoS One; 2015; 10(1):e0116869. PubMed ID: 25607660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Moris D; Damaskos C; Spartalis E; Papalampros A; Vernadakis S; Dimitroulis D; Griniatsos J; Felekouras E; Nikiteas N
    Anticancer Res; 2017 May; 37(5):2185-2194. PubMed ID: 28476781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
    Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
    Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific MAPK-Associated MicroRNAs in Serum Differentiate Pancreatic Cancer from Autoimmune Pancreatitis.
    Akamatsu M; Makino N; Ikeda Y; Matsuda A; Ito M; Kakizaki Y; Saito Y; Ishizawa T; Kobayashi T; Furukawa T; Ueno Y
    PLoS One; 2016; 11(7):e0158669. PubMed ID: 27380024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
    Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. hsa-miR-96 and hsa-miR-217 Expression Down-Regulates with Increasing Dysplasia in Pancreatic Intraepithelial Neoplasias and Intraductal Papillary Mucinous Neoplasms.
    Chang X; Yu C; Li J; Yu S; Chen J
    Int J Med Sci; 2017; 14(5):412-418. PubMed ID: 28539816
    [No Abstract]   [Full Text] [Related]  

  • 8. The association between serum ferritin levels and malignant intraductal papillary mucinous neoplasms.
    Zhuge X; Zhou H; Chen L; Chen H; Chen X; Guo C
    BMC Cancer; 2021 Nov; 21(1):1253. PubMed ID: 34800987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
    Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
    J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Circulating miRNA Signatures for Early Detection of Pancreatic Neoplasia.
    Vila-Navarro E; Duran-Sanchon S; Vila-Casadesús M; Moreira L; Ginès À; Cuatrecasas M; Lozano JJ; Bujanda L; Castells A; Gironella M
    Clin Transl Gastroenterol; 2019 Apr; 10(4):e00029. PubMed ID: 31009404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
    Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
    J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative evaluation of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas: clinical, radiological, and pathological analysis of 123 cases.
    Nara S; Onaya H; Hiraoka N; Shimada K; Sano T; Sakamoto Y; Esaki M; Kosuge T
    Pancreas; 2009 Jan; 38(1):8-16. PubMed ID: 18665010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging role of tumor markers and biochemistry in the preoperative invasive assessment of intraductal papillary mucinous neoplasm of the pancreas.
    You L; Ma L; Zhao WJ; Zhao YP; Dai MH
    Clin Chim Acta; 2016 Feb; 454():89-93. PubMed ID: 26746574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNAs for Detection of Pancreatic Neoplasia: Biomarker Discovery by Next-generation Sequencing and Validation in 2 Independent Cohorts.
    Vila-Navarro E; Vila-Casadesús M; Moreira L; Duran-Sanchon S; Sinha R; Ginés À; Fernández-Esparrach G; Miquel R; Cuatrecasas M; Castells A; Lozano JJ; Gironella M
    Ann Surg; 2017 Jun; 265(6):1226-1234. PubMed ID: 27232245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas.
    Akimoto Y; Nouso K; Kato H; Miyahara K; Dohi C; Morimoto Y; Kinugasa H; Tomoda T; Yamamoto N; Tsutsumi K; Kuwaki K; Onishi H; Ikeda F; Nakamura S; Shiraha H; Takaki A; Okada H; Amano M; Nishimura S; Yamamoto K
    Pancreatology; 2015; 15(4):432-8. PubMed ID: 26052067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma.
    Alemar B; Izetti P; Gregório C; Macedo GS; Castro MA; Osvaldt AB; Matte U; Ashton-Prolla P
    Pancreas; 2016 Jan; 45(1):84-92. PubMed ID: 26262588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inferior head resection of the pancreas for intraductal papillary mucinous neoplasms.
    Nakagohri T; Kinoshita T; Konishi M; Takahashi S; Gotohda N; Kobayashi S; Kojima M; Miyauchi H; Asano T
    J Hepatobiliary Pancreat Sci; 2010 Nov; 17(6):798-802. PubMed ID: 19727540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes.
    Minagawa N; Sato N; Mori Y; Tamura T; Higure A; Yamaguchi K
    Eur J Surg Oncol; 2013 Jun; 39(6):554-8. PubMed ID: 23506840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer.
    Abue M; Yokoyama M; Shibuya R; Tamai K; Yamaguchi K; Sato I; Tanaka N; Hamada S; Shimosegawa T; Sugamura K; Satoh K
    Int J Oncol; 2015 Feb; 46(2):539-47. PubMed ID: 25384963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endoscopic ultrasonographic findings predict the risk of carcinoma in branch duct intraductal papillary mucinous neoplasms of the pancreas.
    Kobayashi N; Sugimori K; Shimamura T; Hosono K; Watanabe S; Kato S; Ueda M; Endo I; Inayama Y; Maeda S; Nakajima A; Kubota K
    Pancreatology; 2012; 12(2):141-5. PubMed ID: 22487524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.